Q-omics provides the consensus-scored IL23R profile across patient tissues and cancer cell-line models. IL23R expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL23R is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, IL23R RNA expression shows 15,041 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where IL23R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL23R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL23R survival associations across molecular data types. IL23R RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL23R RNA expression–survival associations across cancer types. High IL23R expression shows unfavorable associations in LGG, ACC and KIRP, but favorable associations in HNSC, CHOL and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL23R RNA expression.
This table summarizes IL23R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL23R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL23R shows lower tumor expression in COAD, LUSC, KICH, LUAD and CHOL and higher tumor expression in KIRC. The COAD box plot shows higher IL23R RNA expression in normal versus tumor tissue (log2 FC = −0.440, t-test p < 0.001).
This table shows molecular features associated with IL23R in patient tissues and cancer cell lines. In patient samples, IL23R shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IL23R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
